Tandem Diabetes shareholders elect directors, approve board declassification and say-on-pay

TANDEM DIABETES CARE INC

Peyton R. Howell and John F. Sheridan elected as Class III directors with ~98.6% and ~98.1% of votes cast.
Amendment to declassify board (annual elections) approved with 99.9% of votes cast in favor.
Non-binding advisory vote on named executive officer compensation approved with ~98.4% of votes cast.
Ratification of Ernst & Young as independent auditor for FY2022 approved with ~97.7% of votes cast.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.